An UHPLC-MS/MS method to determine FLZ major active metabolites in human plasma: application to a pharmacokinetic study.

Aim: FLZ, a novel promising dopamine neuroprotective agent, is designed to treat Parkinson's disease. F7G and F21G are FLZ major active Phase II metabolites whose exposure are nearly 100-times higher than FLZ, may chiefly produce effectiveness in human. Measurement of F7G and F21G in plasma samples is critical for investigating its pharmacokinetics in clinical studies. Methodology & results: Plasma samples were extracted by SPE method and then analyzed by a newly established ultra-UHPLC-MS/MS method. Conclusion: For the first time, a reliable and robust bioanalytical method for F7G and F21G detection was successfully applied in a first-in-human study.

[1]  Wei Wang,et al.  Simultaneous determination of FLZ and its metabolite (M1) in human plasma and urine by UHPLC‐MS/MS: Application to a pharmacokinetic study , 2019, Journal of pharmaceutical and biomedical analysis.

[2]  J. Dai,et al.  Enzymatic synthesis of glucuronidated metabolites of two neurological active agents using plant glucuronosyltransferases , 2018, Journal of Asian natural products research.

[3]  Y. Mechref,et al.  Characterization of isomeric glycan structures by LC‐MS/MS , 2017, Electrophoresis.

[4]  X. Bao,et al.  A novel synthetic derivative of squamosamide FLZ inhibits the high mobility group box 1 protein-mediated neuroinflammatory responses in murine BV2 microglial cells , 2017, Naunyn-Schmiedeberg's Archives of Pharmacology.

[5]  O. Tysnes,et al.  Epidemiology of Parkinson’s disease , 2017, Journal of Neural Transmission.

[6]  Dan Zhang,et al.  Squamosamide derivative FLZ protected tyrosine hydroxylase function in a chronic MPTP/probenecid mouse model of Parkinson’s disease , 2015, Naunyn-Schmiedeberg's Archives of Pharmacology.

[7]  Nicholas Gray,et al.  European Bioanalysis Forum: recommendation on dealing with hemolyzed and hyperlipidemic matrices. , 2014, Bioanalysis.

[8]  X. Bao,et al.  Squamosamide derivative FLZ protected dopaminergic neuron by activating Akt signaling pathway in 6-OHDA-induced in vivo and in vitro Parkinson's disease models , 2014, Brain Research.

[9]  Xiaoliang Wang,et al.  Inhibition of Src tyrosine kinase activity by squamosamide derivative FLZ attenuates neuroinflammation in both in vivo and in vitro Parkinson's disease models , 2013, Neuropharmacology.

[10]  F. Fang,et al.  FLZ, synthetic squamosamide cyclic derivative, attenuates memory deficit and pathological changes in mice with experimentally induced aging , 2012, Naunyn-Schmiedeberg's Archives of Pharmacology.

[11]  X. Bao,et al.  FLZ protects dopaminergic neuron through activating protein kinase B/mammalian target of rapamycin pathway and inhibiting RTP801 expression in Parkinson's disease models , 2012, Neuroscience.

[12]  X. Bao,et al.  FLZ, a novel HSP27 and HSP70 inducer, protects SH-SY5Y cells from apoptosis caused by MPP+ , 2011, Brain Research.

[13]  Xiaoming Hu,et al.  Squamosamide derivative FLZ protects dopaminergic neurons against inflammation-mediated neurodegeneration through the inhibition of NADPH oxidase activity , 2008, Journal of Neuroinflammation.

[14]  Jian-Jun Zhang,et al.  The novel squamosamide derivative FLZ protects against 6-hydroxydopamine-induced apoptosis through inhibition of related signal transduction in SH-SY5Y cells. , 2007, European journal of pharmacology.

[15]  Jian-Jun Zhang,et al.  The novel squamosamide derivative (compound FLZ) attenuated 1-methyl, 4-phenyl-pyridinium ion (MPP+)-induced apoptosis and alternations of related signal transduction in SH-SY5Y cells , 2007, Neuropharmacology.

[16]  Dan Zhang,et al.  FLZ Attenuates α-Synuclein-Induced Neurotoxicity by Activating Heat Shock Protein 70 , 2015, Molecular Neurobiology.

[17]  Yuan-Qing Xia,et al.  Systematic LC-MS/MS bioanalytical method development that incorporates plasma phospholipids risk avoidance, usage of incurred sample and well thought-out chromatography. , 2010, Biomedical chromatography : BMC.

[18]  Geng-tao Liu,et al.  Pharmacological study of the novel compound FLZ against experimental parkinson’s models and its active mechanism , 2007, Molecular Neurobiology.